Compare Kinross Gold Corporation (KGC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Summit Therapeutics Inc — how do they compare? Kinross Gold Corporation trades at $27.62 (market cap $32.29B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Kinross Gold Corporation is far larger — about 2.7× Summit Therapeutics Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KGC | SMMT | |
|---|---|---|
Market Cap | $32.29B | $12.06B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $26.98 |
52-Week Low | $18.70 | $12.55 |
Enterprise Value | $30.37B | $11.39B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.
The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
